rhIL-2与阿霉素白蛋白磁微球靶向治疗肿瘤的协同作用

目的：观察重组人白细胞介素-2(rhIL-2)瘤内注射和阿霉素白蛋白磁微球(ADM-MAM)联合外磁场联合治疗H22荷瘤小鼠的协同作用，并探讨其抗肿瘤作用机制。方法：以荷瘤小鼠的瘤重为指标，观察药物的抗肿瘤活性。以乳酸脱氢酶释放法测NK细胞的杀伤活性。以MTT比色法测淋巴细胞的转化率。以流式细胞术检测肿瘤细胞的凋亡及p53、Fas和FasL的表达。用RT—PCR法测定IL—2及IL—12的表达。探讨抗肿瘤机制。结果：ADM—MAM靶向治疗与rhIL—2联用，可显著减小荷瘤小鼠的瘤重；提高NK细胞的杀伤活性和脾脏淋巴细胞的转化率；减小肿瘤细胞的增殖指数，上调肿瘤细胞p53、Fas和FasL的表达，以及增加脾脏淋巴细胞上IL—2及IL—12的表达。结论：ADM—MAM联合外磁场，具有显著增强抑瘤的作用。rhIL—2能增强ADM—MAM靶向治疗的抗肿瘤作用，其抗肿瘤协同作用主要是通过促进T细胞增殖，刺激NK细胞增长等提高机体的免疫功能而实现的。

Cooperative effect of rhIL-2 and adriamycin-magnetic albumin microsphere targeting therapy on tumor

AIM: To observe the synergistic inhibitory effects of rhlL-2 and adriamycin-magnetic albumin microsphere(ADM-MAM) targeting therapy on tumor and to explore their antitumor mechanism. METHODS: The antitumor activity was observed using the tumor weight as index. The killer activity of natural killer (NK) cells and the lymphocyte transformation were examined by the LDH release assay and MTT colori-metry, respectively. The apoptosis of tumor cells and the expressions of p53, Fas and FasL were examined by flow cytometry. The expressions of IL-2 and IL-12 were determined by RT-PCR. RESULTS: Compared with the control group, in ADM-MAM targeting therapy group and combination therapy (ADM-MAM and rhlL-2 therapy) group, tumor weight, killer activity of NK cells, and the lymphocyte transformation; were obviously decreased: while the expression of Fas, FasL, IL-2 and IL-12 were markedly increased. CONCLUSION: ADM-MAM targeting therapy exerts anti-tumor effects with fewer side effects, which can be enhanced when combined with rhlL-2 therapy. Such synergistic anti-tumor effects may be realized by stimulating the proliferation of T cells and growth of NK cell to enhance cellular immunologic function.